Tachyon Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tachyon Therapeutics, Inc. - overview
Established
2020
Location
San Francisco, CA, US
Primary Industry
Pharmaceuticals
About
Based in San Francisco, US, and founded in 2020, Tachyon Therapeutics, Inc. , develops therapeutics against new drug targets in cancer biology. In March 2023, Tachyon Therapeutics, Inc. raised USD 11.
6 million in venture funding from investors Khosla Ventures, Red Tree Venture Capital, and Veblen Ventures. As of 2023, the company is led by its CEO, Frank Perabo. Tachyon Therapeutics offers single-cell genomic analysis technology used for the treatment of various cancer types, such as colorectal, esophageal, breast, and lymphoma. The company’s therapeutic solution helps reduce tumor-initiating cancer stem cells responsible for relapses and metastases.
The company plans to use the March 2023 funding to progress the company's portfolio of new cancer drug candidates as well as conduct the Phase 1 clinical trial in advanced solid tumours.
Current Investors
California Institute for Regenerative Medicine, Khosla Ventures, Red Tree Venture Capital
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals, Pharmaceuticals, Pharmaceutical Research & Development
Website
www.tachyontx.com
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.